I'm independently developing the world's first gastric disease vaccine to complete Phase III clinical trials

the scientific research team led by Professor Zhai Quanming, director of the Biomedicine Pilot Research Base and Clinical Immunology and Microbiology Research Office of the Third Military Medical University, has completed the Phase III clinical trial of the new class I drug "Oral Recombinant Helicobacter pylori vaccine" after more than 10 years, and is expected to be officially put into production in the near futureThis is the first international completion of Phase III clinical trials of The HPneumococcal gastric disease vaccine, is truly developed by Chinese original vaccineAt present, the subject has been five national invention patentsIn 1983, Australian scholars Marshall and Warren discovered H.Pylori (HPylori, Hp), which is found to be the cause of gastritis, stomach ulcers and duodenal ulcersThe World Health Organization subsequently identified Hp bacteria as a class I carcinogen, for which two Australian scientists won the 2005 Nobel Prize in Physiology/Medical SciencesSince then, how to effectively prevent and cure has become a difficult problem in the international medical communityIn 1995, Yu Quanming led the team in the absence of the same vaccine reference materials, genetic engineering, protein engineering and other modern molecular biotechnology and the original research basis closely linked to the development of many key technical difficulties, the international first-in-the-way molecular adjunic mucosa vaccine theory, and adopt a unique genetic engineering vaccine molecular construction model, on the surface of the mucous membrane to produce immunity In the past, it was difficult to prevent and control the infection of Helicobacter pylori on the surface of the mucosa, a variety of long-term stable animal infection models were established, which provided the necessary conditions for evaluating gastric disease vaccine, successfully solved the worldwide problems in this field, and adopted special process dosage forms to overcome the destructive effectofle of gastric acid and gastric protease on the vaccine, and improved the effectiveness and stability of the vaccineIn 1997, the Three Military Medical University in the form of technology shares, the formation of production, learning, research mode of biological high-tech Co., Ltd., the construction of advancedGMPbiopharmaceutical engineering technology research center, so that the project funds, research and development equipment has been guaranteedThe project has been listed as the national "95" key issues, the national "15" major scientific and technological special topics, the national "863" topic, the National New Drug Fund project, military medical research projects, the National Natural Science Foundation project(According to Science and Technology Daily)